INFINITY PHARMACEUTICALS, INC. Form 8-K

November 08, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 3, 2010

Infinity Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

Delaware (State or Other Jurisdiction

000-31141 (Commission 33-0655706 (IRS Employer

of Incorporation) File Number) Identification No.)

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 8-K

780 Memorial Drive, Cambridge, MA
(Address of Principal Executive Offices)

Registrant s telephone number, including area code: (617) 453-1000
(Zip Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 3, 2010, Steven H. Holtzman, the current Executive Chair of our Board of Directors, provided notice that effective December 31, 2010 he will transition from Executive Chair to non-executive Chair of our Board of Directors.

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 8, 2010

INFINITY PHARMACEUTICALS, INC.

By: /s/ Gerald E. Quirk

Gerald E. Quirk

Vice President, Corporate Affairs and General Counsel